Reda Z. Mahfouz
YOU?
Author Swipe
View article: Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progression
Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progression Open
Chronic obstructive pulmonary disease (COPD) and lung cancer represent formidable challenges in global health, characterized by intricate pathophysiological mechanisms and multifaceted disease progression. This comprehensive review integra…
View article: Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progressions
Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progressions Open
Keywords: Chronic Obstructive Pulmonary Disease (COPD), Long Non-Coding RNAs (lncRNAs), Molecular Pathogenesis, Inflammation, Lung Cancer, Diagnostic Biomarkers
View article: Flow cytometry of <scp>DNMT1</scp> as a biomarker of hypomethylating therapies
Flow cytometry of <span>DNMT1</span> as a biomarker of hypomethylating therapies Open
The 5‐azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation‐inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postal…
View article: Data from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Data from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy Open
Purpose: The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA-methyltransferase 1 (DNMT1). This action is S-phase dependent. Hence,…
View article: Data from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Data from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy Open
Purpose: The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA-methyltransferase 1 (DNMT1). This action is S-phase dependent. Hence,…
View article: Supplementary Figure 1 from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Supplementary Figure 1 from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy Open
PDF file - 297K, Figure S1: CDA mRNA expression in various human tissues. Figure S2: CDA mRNA expression in primary cancer cells. Figure S3: Incidence of MDS in the United States.
View article: Supplementary Figure 1 from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Supplementary Figure 1 from Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy Open
PDF file - 297K, Figure S1: CDA mRNA expression in various human tissues. Figure S2: CDA mRNA expression in primary cancer cells. Figure S3: Incidence of MDS in the United States.
View article: Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation Open
Summary T‐cell large granular lymphocytic leukaemia (T‐LGLL) is a chronic clonal lymphoproliferative disorder of cytotoxic T lymphocytes which commonly occurs in older patients and is often associated with autoimmune diseases. Among 246 pa…
View article: Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies
Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies Open
Summary The nucleoside analogue decitabine can deplete the epigenetic regulator DNA methyltransferase 1 (DNMT1), an effect that occurs, and is saturated at, low concentrations/doses. A reason to pursue this molecular‐targeted effect instea…
View article: Impact of germline <i><scp>CTC</scp>1</i> alterations on telomere length in acquired bone marrow failure
Impact of germline <i><span>CTC</span>1</i> alterations on telomere length in acquired bone marrow failure Open
Summary Compound heterozygous germline mutations in CTC 1 gene have been found in patients with atypical dyskeratosis congenita ( DC ), whereas heterozygous carriers are unaffected. Through screening of a large cohort of adult patients wit…
View article: Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion
Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion Open
The DNA hypomethylating agents decitabine and 5-azacytidine are the only two drugs approved for treatment of all subtypes of the myeloid malignancy myelodysplastic syndromes (MDS). The key to drug activity is incorporation into target cell…
View article: Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates Open
Nucleophosmin (NPM1) is among the most frequently mutated genes in acute myeloid leukemia (AML). It is not known, however, how the resulting oncoprotein mutant NPM1 is leukemogenic. To reveal the cellular machinery in which NPM1 participat…
View article: Origins of myelodysplastic syndromes after aplastic anemia
Origins of myelodysplastic syndromes after aplastic anemia Open
To the editor:
The course of aplastic anemia (AA) is often complicated by the development of clonal disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and secondary myelodysplastic syndromes (sMDS).[1][1][⇓][2][⇓][3][⇓][4]-[5][5]…
View article: Comparison of intrathecal versus intra-articular dexmedetomidine as an adjuvant to bupivacaine on postoperative pain following knee arthroscopy: a randomized clinical trial
Comparison of intrathecal versus intra-articular dexmedetomidine as an adjuvant to bupivacaine on postoperative pain following knee arthroscopy: a randomized clinical trial Open
Both intrathecal and intra-articular dexmedetomidine enhanced postoperative analgesia after arthroscopic knee surgery. Less total meperidine was required with intra-articular administration to extend postoperative analgesia to 6 h with hem…
View article: IL-8 mRNA and Serum Levels in Vitiligo Patients: A Case Control Study
IL-8 mRNA and Serum Levels in Vitiligo Patients: A Case Control Study Open
Introduction: Many theories are suggested to explain aetiology of vitiligo, such as autoimmune, genetic and biochemical. Interleukin-8 (IL-8) is a pro-inflammatory chemokine which is evaluated in the pathogenesis of some skin diseases, lik…
View article: Recurrent genetic defects on chromosome 5q in myeloid neoplasms
Recurrent genetic defects on chromosome 5q in myeloid neoplasms Open
Our results illuminate the spectrum of molecular defects characteristic of del(5q), their clinical impact and succession of stepwise evolution.
View article: Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes Open
NIH (R01CA138858, CA043703); Department of Defense (PR081404); Clinical and Translational Science Award (CTSA) (UL1RR024989); and the Leukemia and Lymphoma Society (Translational Research Program).
View article: DNA Methyltransferase-1 (DNMT1): A Flow Cytometric Pharmacodynamic Assay for Azacitidine Hypomethylating Therapy after Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT)
DNA Methyltransferase-1 (DNMT1): A Flow Cytometric Pharmacodynamic Assay for Azacitidine Hypomethylating Therapy after Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Open
Disease relapse is a major cause of treatment failure following alloSCT for acute myeloid leukemia (AML). Azacitidine has shown efficacy in treating, and preventing, post-transplant relapse in patients with AML. Post-SCT azacitidine admini…